Histologic Improvement With Vedolizumab vs Adalimumab in Ulcerative Colitis: Results From VARSITY

(1) Nancy University Hospital,Nancy,France

(2) Icahn School of Medicine at Mount Sinai,New York,United States

(3) Mayo Clinic College of Medicine,Rochester,United States

(4) Humanitas University,Milan,Italy

(5) Takeda,London,United Kingdom

(6) Takeda,Cambridge,United States

(7) Icahn School of Medicine at Mount Sinai,New York City,United States

(8) University-Hospital Schleswig-Holstein,Kiel,Germany



This item was part of the Randomised controlled trials in IBD I session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019